Idioma:

Fluid and Biopsy Based Biomarkers in Parkinson's Disease

Coughlin, David G. ; Irwin, David J.

Neurotherapeutics, 2023-07, Vol.20 (4), p.932-954 [Periódico revisado por pares]

Cham: Elsevier Inc

Texto completo disponível

Citações Citado por

Enviar para

Título:
Fluid and Biopsy Based Biomarkers in Parkinson's Disease
Autor: Coughlin, David G. ; Irwin, David J.
Assuntos: Alpha-synuclein ; alpha-Synuclein - metabolism ; Alzheimer Disease ; Alzheimer's disease ; Amyloid beta-Peptides ; Autopsy ; Biomarkers ; Biomedical and Life Sciences ; Biomedicine ; Biopsy ; Cerebrospinal fluid ; Dementia ; Dementia disorders ; Humans ; Immunofluorescence ; Immunohistochemistry ; Lewy bodies ; Movement disorders ; Neurobiology ; Neurodegenerative diseases ; Neurology ; Neurosciences ; Neurosurgery ; Parkinson Disease - diagnosis ; Parkinson Disease - pathology ; Parkinson's disease ; Pathology ; Protein folding ; Protein misfolding cyclic amplification ; Protein seeding ; Real-time quaking induced conversion ; Review ; Synuclein ; Tau protein
É parte de: Neurotherapeutics, 2023-07, Vol.20 (4), p.932-954
Notas: ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-2
Descrição: Several advances in fluid and tissue-based biomarkers for use in Parkinson's disease (PD) and other synucleinopathies have been made in the last several years. While work continues on species of alpha-synuclein (aSyn) and other proteins which can be measured from spinal fluid and plasma samples, immunohistochemistry and immunofluorescence from peripheral tissue biopsies and alpha-synuclein seeding amplification assays (aSyn-SAA: including real-time quaking induced conversion (RT-QuIC) and protein misfolding cyclic amplification (PMCA)) now offer a crucial advancement in their ability to identify aSyn species in PD patients in a categorical fashion (i.e., of aSyn + vs aSyn −); to augment clinical diagnosis however, aSyn-specific assays that have quantitative relevance to pathological burden remain an unmet need. Alzheimer's disease (AD) co-pathology is commonly found postmortem in PD, especially in those who develop dementia, and dementia with Lewy bodies (DLB). Biofluid biomarkers for tau and amyloid beta species can detect AD co-pathology in PD and DLB, which does have relevance for prognosis, but further work is needed to understand the interplay of aSyn tau, amyloid beta, and other pathological changes to generate comprehensive biomarker profiles for patients in a manner translatable to clinical trial design and individualized therapies.
Editor: Cham: Elsevier Inc
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Fluid and Biopsy Based Biomarkers in Parkinson's Disease

Coughlin, David G. ; Irwin, David J.

Cham: Elsevier Inc

Buscando em bases de dados remotas. Favor aguardar.